Sign In
Buy UTHR
$549.47
+9.42 (+1.74%)
At Close: Jun 03, 2026
United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 Transcript
03:18pm, Monday, 09'th Mar 2026
United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 Transcript
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors
Ray Kurzweil Sells 4,910 Shares of United Therapeutics (NASDAQ:UTHR) Stock
05:02am, Saturday, 07'th Mar 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) Director Ray Kurzweil sold 4,910 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock
05:02am, Saturday, 07'th Mar 2026
United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the company's stock in a transaction dated Thursday, March 5th. The shares were sold at an average
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
07:00am, Tuesday, 03'rd Mar 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer,
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04:27pm, Monday, 02'nd Mar 2026
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
06:38am, Monday, 02'nd Mar 2026
United Therapeutics said on Monday its experimental pill for a type of blood pressure disorder met all the main and secondary goals of a late-stage study.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADV
Andra AP fonden Reduces Stock Position in United Therapeutics Corporation $UTHR
03:14am, Friday, 27'th Feb 2026
Andra AP fonden lowered its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by 37.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owne
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings
01:54pm, Thursday, 26'th Feb 2026
United Therapeutics Corp (NASDAQ: UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.
United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team
11:30am, Thursday, 26'th Feb 2026
United Therapeutics Corporation delivered strong Q4 and FY2025 results, with revenues up 10%+ and net income per share up ~14%, driving a >75% stock rally. UTHR's Tyvaso remains the dominant PAH franc
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance
10:06am, Thursday, 26'th Feb 2026
United Therapeutics Q4 earnings beat estimates, Tyvaso DPI sales jump 24% despite revenue miss.
2,341 Shares in United Therapeutics Corporation $UTHR Purchased by Empirical Asset Management LLC
05:05am, Thursday, 26'th Feb 2026
Empirical Asset Management LLC acquired a new stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) in the third quarter, according to its most recent disclosure with the Securities and Ex
United Therapeutics Q4 Earnings Call Highlights
05:05am, Thursday, 26'th Feb 2026
United Therapeutics (NASDAQ: UTHR) used its fourth-quarter 2025 corporate update webcast to highlight what executives described as a set of near-term product and clinical milestones aimed at reshaping
